Navigation Links
Vanderbilt scientists report first effective medical therapy for rare stomach disorder
Date:11/25/2009

A drug used to treat colorectal cancer also can reverse a rare stomach disorder and should be considered first-line therapy for the disease, researchers at Vanderbilt University Medical Center report this week.

Mntrier's disease causes thickening of the stomach lining, severe abdominal pain, nausea and vomiting, as well as anemia and swelling in the feet and ankles due to protein loss. Patients are at increased risk for gastric cancer. Previously, the only effective treatment was gastrectomy surgical removal of the stomach.

The targeted cancer drug cetuximab, brand name Erbitux, relieved symptoms of severe Mntrier's disease in seven patients who completed a one-month course of treatment. Four of them showed near-complete remission, the Vanderbilt researchers report in the Nov. 25 issue of the journal Science Translational Medicine.

"We have identified the first effective medical therapy for this disorder," said Robert Coffey, M.D., Ingram Professor of Cancer Research and the paper's senior author.

Erbitux is a monoclonal antibody that blocks the binding of transforming growth factor-alpha, or TGF-alpha, a signaling protein, to the epidermal growth factor (EGF) receptor. Patients with Mntrier's disease have abnormally high levels of TGF-alpha.

In studies dating back 20 years, Coffey and his colleagues found that TGF-alpha causes proliferation of the stomach lining and stimulates mucous production while suppressing acid secretion. Transgenic mice that over-express TGF-alpha in the stomach exhibit all of the hallmarks of Mntrier's disease.

The current study involved nine patients who were considering gastrectomy. Two patients dropped out of the study, but the rest experienced significant relief of symptoms within hours or days after beginning treatment. All seven continued taking the drug after the monthlong study ended.

Of the four patients who experienced near-complete remission of the disease, one of them, and the other three patients in the study, later underwent gastrectomy. Two patients are no longer taking the drug, and one of them has a normal stomach and remains symptom-free two years later, Coffey said.


'/>"/>

Contact: Bill Snyder
william.snyder@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Ovarian Cancer Coalition Partners With Consuelo Vanderbilt Costin
2. Vanderbilt Experts For Health Care Debate
3. Vanderbilt joins national consortium to develop new cancer therapies
4. Vanderbilt researchers pioneer an advanced sepsis detection and management system
5. NIH-funded Vanderbilt Research Seeks Ways to Avoid Information Overload in Health Care Choices Among Seniors
6. Vanderbilt University Medical Center and Waters Collaborate on Tissue Imaging Research Using SYNAPT HDMS
7. Vanderbilt Medical Center chosen as Evidence-based Practice Center
8. Vanderbilt nets brain gene research center
9. Childrens Hospital Oakland scientists discover soy component may be key to fighting colon cancer
10. BIDMC scientists awarded grants from Michael J. Fox Foundation for Parkinsons research
11. Scientists find molecular trigger that helps prevent aging and disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
(Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... ... 05, 2016 , ... At its annual meeting held last week, the American ... National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We ... Chambers , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... CENTENNIAL, Colo. , Feb. 5, 2016  As ... about health. The multitude of recommended screenings and tests ... healthy aging a priority. However, for the majority of ... of proactive health planning. For the 37.5 million American ... time like the present to make hearing health a ...
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
Breaking Medicine Technology: